Short Anabolic Peptides for Bone Growth

Medicinal Research Reviews

Volumn 36, Issue 4, 2016, Pages 579-640

  Amso, Zaid ^a   Cornish, Jillian ^a   Brimble, Margaret A ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

anabolic peptides; bone formation; medicinal chemistry; osteoblast activity; osteoporosis

Indexed keywords

AMYLIN; ANABOLIC AGENT; APELIN; BONE MORPHOGENETIC PROTEIN; C PEPTIDE; COLLAGEN; COLLAGEN BINDING PROTEIN; DIANTHIN G; DIANTHIN H; ENDOTHELIN 1; GALANIN; GHRELIN; GROWTH HORMONE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTEGRIN; NATRIURETIC PEPTIDE TYPE C; OREXIN; OSTEOBLAST ACTIVATING PEPTIDE; OSTEOGENIC GROWTH PEPTIDE; OSTEOPONTIN; PANCREAS HORMONE; PARATHYROID HORMONE; PEPTIDE; PEPTIDE E; PEPTIDE FRAGMENT; PEPTIDE HORMONE; PREPTIN; RUSALATIDE; SUBSTANCE P; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

BONE GROWTH; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL (TOPIC); DRUG BINDING; DRUG SPECIFICITY; HORMONAL THERAPY; HUMAN; NERVOUS SYSTEM; NONHUMAN; REVIEW;

EID: 84974694608     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21388     Document Type: Review

References (402)

1. Mazziotti G, Bilezikian J, Canalis E, Cocchi D, Giustina A. New understanding and treatments for osteoporosis. Endocrine 2012;41(1):58–69.
2. Harvey N, Dennison E, Cooper C. Osteoporosis: impact on health and economics. Nat Rev Rheumatol 2010;6:99–105.
3. Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA. Osteoporosis in the European Union: Medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013;8(136):1–115.
4. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: Now and the future. Lancet 2011;377(9773):1276–1287.
5. Dawson–Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ, 3rd. The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int 2010;21(1):41–52.
6. National Osteoporosis Foundation. http://www.nof.org/home.
7. Reid IR. Anti-resorptive therapies for osteoporosis. Semin Cell Dev Biol 2008;19(5):473–478.
8. Kraenzlin ME, Meier C. Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol 2011;7(11):647–656.
9. Reid IR. Short-term and long–term effects of osteoporosis therapies. Nat Rev Endocrinol 2015;11(7):418–428.
10. Reid IR. Efficacy, effectiveness and side effects of medications used to prevent fractures. J Intern Med 2015;277(6):690–706.
11. Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chem Biol Drug Des 2013;81(1):136–147.
12. Krause C, de Gorter DJJ, Karperien M, ten Dijke P, Asbmr. Chapter 2. Signal Transduction Cascades Controlling Osteoblast Differentiation. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. New Jersey: John Wiley & Sons, Inc.; 2009. pp 10–16.
13. Guo J, Liu M, Yang D, Bouxsein ML, Thomas CC, Schipani E, Bringhurst FR, Kronenberg HM. Phospholipase C signaling via the parathyroid hormone (PTH)/PTH-related peptide receptor is essential for normal bone responses to PTH. Endocrinology 2010;151(8):3502–3513.
14. Baron R, Hesse E. Update on bone anabolics in osteoporosis treatment: Rationale, current status, and perspectives. J Clin Endocrinol Metab 2012;97(2):311–325.
15. Romero G, Sneddon WB, Yang Y, Wheeler D, Blair HC, Friedman PA. Parathyroid hormone receptor directly interacts with dishevelled to regulate beta-Catenin signaling and osteoclastogenesis. J Biol Chem 2010;285(19):14756–14763.
16. Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: A decade of experience. J Bone Miner Res 2012;27(12):2419–2428.
17. Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 1997;82(2):620–628.
18. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 2003;278(50):50259–50272.
19. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB. Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomized trial. Ann Intern Med 2007;146(5):326–339.
20. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mellström D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344(19):1434–1441.
21. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R. Efficacy and safety of human parathyroid hormone-(1–84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003;88(11):5212–5220.
22. Blick SK, Dhillon S, Keam SJ. Teriparatide: A review of its use in osteoporosis. Drugs 2008;68(18):2709–2737.
23. Cranney A, Papaioannou A, Zytaruk N, Hanley D, Adachi J, Goltzman D, Murray T, Hodsman A. Parathyroid hormone for the treatment of osteoporosis: A systematic review. Can Med Assoc J 2006;175(1):52–59.
24. Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 2010;47(3):493–502.
25. Rubin MR, Bilezikian JP. The anabolic effects of parathyroid hormone therapy. Clin Geriatr Med 2003;19(2):415–432.
26. Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 2012;97(9):3097–3106.
27. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007;40(6):1434–1446.
28. Canalis E. Update in new anabolic therapies for osteoporosis. J Clin Endocrinol Metab 2010;95(4):1496–1504.
29. Song J, Jing Z, Chang F, Li L, Su Y. Single and combined use of human parathyroid hormone (PTH) (1-34) on areal bone mineral density (aBMD) in postmenopausal women with osteoporosis: Evidence based on 9 RCTs. Med Sci Monit 2014;20:2624–2632.
30. Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357(20):2028–2039.
31. Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, Garcia-Hernandez PA, Recknor CP, Einhorn TA, Dalsky GP, Mitlak BH, Fierlinger A, Lakshmanan MC. Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2010;25(2):404–414.
32. Miyakoshi N, Aizawa T, Sasaki S, Ando S, Maekawa S, Aonuma H, Tsuchie H, Sasaki H, Kasukawa Y, Shimada Y. Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: A comparison between treatment with and without teriparatide. J Bone Miner Metab 2015;33(5):553–559.
33. Eriksen EF, Keaveny TM, Gallagher ER, Krege JH. Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis. Bone 2014;67:246–256.
34. Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004;32(4):426–438.
35. Miller PD. Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep 2008;6(1):12–16.
36. Bonafede MM, Shi N, Bower AG, Barron RL, Grauer A, Chandler DB. Teriparatide treatment patterns in osteoporosis and subsequent fracture events: A US claims analysis. Osteoporos Int 2015;26(3):1203–1212.
37. Isogai Y, Takao-Kawabata R, Takakura A, Sugimoto E, Nakazono O, Ikegaki I, Kuriyama H, Ishizuya T. Early effects of single and low-frequency repeated administration of teriparatide, hPTH(1-34), on bone formation and resorption in ovariectomized rats. Calcif Tissue Int 2015;97(4):412–420.
38. Ponnapakkam T, Katikaneni R, Miller E, Ponnapakkam A, Hirofumi S, Miyata S, Suva LJ, Sakon J, Matsushita O, Gensure RC. Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice. Calcif Tissue Int 2011;88(6):511–520.
39. Ponnapakkam T, Katikaneni R, Suda H, Miyata S, Matsushita O, Sakon J, Gensure RC. A single injection of the anabolic bone agent, parathyroid hormone-collagen binding domain (PTH-CBD), results in sustained increases in bone mineral density for up to 12 months in normal female mice. Calcif Tissue Int 2012;91(3):196–203.
40. Hammerle SP, Mindeholm L, Launonen A, Kiese B, Loeffler R, Harfst E, Azria M, Arnold M, John MR. The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. Bone 2012;50(4):965–973.
41. Daddona PE, Matriano JA, Mandema J, Maa YF. Parathyroid hormone (1-34)-coated microneedle patch system: Clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharm Res 2011;28(1):159–165.
42. Cosman F, Lane NE, Bolognese MA, Zanchetta JR, Garcia-Hernandez PA, Sees K, Matriano JA, Gaumer K, Daddona PE. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2010;95(1):151–158.
43. Matsumoto T, Shiraki M, Hagino H, Iinuma H, Nakamura T. Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: A pilot study. Osteoporos Int 2006;17(10):1532–1538.
44. Farra R, Sheppard NF, McCabe L, Neer RM, Anderson JM, Santini JT, Cima MJ, Langer R. First-in-human testing of a wirelessly controlled drug delivery microchip. Sci Transl Med 2012;4(122):122ra21.
45. Whitfield JF, Morley P, Willick GE, Ross V, Barbier JR, Isaacs RJ, Ohannessian-Barry L. Stimulation of the growth of femoral trabecular bone in ovariectomized rats by the novel parathyroid hormone fragment, hPTH-(1-31)NH2 (ostabolin). Calcif Tissue Int 1996;58(2):81–87.
46. Whitfield JF, Morley P, Willick GE, Ross V, Langille R, MacLean S, Barbier J, Isaacs RJ, Ohannessian-Barry L. Comparison of the abilities of human parathyroid hormone(1-31)NH2 and human parathyroid hormone-related protein(1-31)NH2 to stimulate femoral trabecular bone growth in ovariectomized rats. Calcif Tissue Int 1997;61(4):322–326.
47. Henriksen K, Andersen JR, Riis BJ, Mehta N, Tavakkol R, Alexandersen P, Byrjalsen I, Valter I, Nedergaard BS, Teglbjaerg CS, Stern W, Sturmer A, Mitta S, Nino AJ, Fitzpatrick LA, Christiansen C, Karsdal MA. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis. Bone 2013;53(1):160–166.
48. Whitfield JF, Morley P, Willick G, Langille R, Ross V, MacLean S, Barbier JR. Cyclization by a specific lactam increases the ability of human parathyroid hormone (hPTH)-(1-31)NH2 to stimulate bone growth in ovariectomized rats. J Bone Miner Res 1997;12(8):1246–1252.
49. Hodsman A, Bone H, Gallagher C. Ostabolin-C increases lumbar spine and hip BMD after 1 year of therapy: Results of a phase II clinical trial. J Bone Miner Res 2007;22(Suppl 1):S38.
50. Morley P, Bishop J, andersen R. Pulmonary delivery of the parathyroid hormone analogue ostabolin-CTM stimulates markers of bone formation in postmenopausal women. J Bone Miner Res 2007;22(Suppl 1):S127.
51. Neerup TSR, Stahlhut M, Petersen JS, Daugaard JR, Jensen J-EB, Peng Z, Morko J, Thorkildsen C. ZP2307, a novel, cyclic PTH(1-17) analog that augments bone mass in ovariectomized rats. Bone 2011;48(6):1319–1327.
52. Kronenberg HM. Developmental regulation of the growth plate. Nature 2003;423(6937):332–336.
53. Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003;88(2):569–575.
54. Horwitz MJ, Augustine M, Khan L, Martin E, Oakley CC, Carneiro RM, Tedesco MB, Laslavic A, Sereika SM, Bisello A, Garcia-Ocana A, Gundberg CM, Cauley JA, Stewart AF. A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: The PrOP study. J Bone Miner Res 2013;28(11):2266–2276.
55. Obaidi M, Chavira R, Reinbolt L, Offman E, McKay E, O'Dea L. Pharmacokinetics and pharmacodynamic of subcutaneously (SC) administered doses of BA058, a bone mass density restoring agent in healthy postmenopausal women. AAPS 2010 (abstract);W5385.
56. Doyle N, Varela A, Smith S, Guldberg R, Hattersley G. Long term effect of BA058, a novel human PTHrP analog, Restores bone mass in the aged osteopenic ovariectomized cynomolgus monkeys. J Bone Miner Res 2013;28(Suppl 1)(abstract).
57. Hattersley G, Lesage E, Varela A, Mith S. BA058, a novel human PTHrP analog, restores bone density and increases bone strength at the spine and femur in osteopenic rats. Endocr Rev 2013;34(abstract).
58. Leder BZ, O'Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2015;100(2):697–706.
59. Radius Health. http://ir.radiuspharm.com/releasedetail.cfm?ReleaseID=9362012015.
60. McKay B, Sandhu HS. Use of recombinant human bone morphogenetic protein-2 in spinal fusion applications. Spine 2002;27(16S):S66–S85.
61. Jones AL, Bucholz RW, Bosse MJ, Mirza SK, Lyon TR, Webb LX, Pollak AN, Golden JD, Valentin-Opran A. Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg Am 2006;88(7):1431–1441.
62. Schmierer B, Hill CS. TGFbeta-SMAD signal transduction: Molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 2007;8(12):970–982.
63. Zerath E, Holy X, Noel B, Malouvier A, Hott M, Marie PJ. Effects of BMP-2 on osteoblastic cells and on skeletal growth and bone formation in unloaded rats. Growth Horm IGF Res 1998;8(2):141–149.
64. Boden SD. The ABCs of BMPs. Orthop Nurs 2005;24(1):49–52.
65. Khan SN, Lane JM. The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in orthopaedic applications. Expert Opin Biol Ther 2004;4(5):741–748.
66. Suzuki Y, Tanihara M, Suzuki K, Saitou A, Sufan W, Nishimura Y. Alginate hydrogel linked with synthetic oligopeptide derived from BMP-2 allows ectopic osteoinduction in vivo. J Biomed Mater Res 2000;50(3):405–409.
67. Saito A, Suzuki Y, Ogata S, Ohtsuki C, Tanihara M. Activation of osteo-progenitor cells by a novel synthetic peptide derived from the bone morphogenetic protein-2 knuckle epitope. Biochim Biophys Acta 2003;23:1–2.
68. Saito A, Suzuki Y, Ogata S, Ohtsuki C, Tanihara M. Accelerated bone repair with the use of a synthetic BMP-2-derived peptide and bone-marrow stromal cells. J Biomed Mater Res 2005;72(1):77–82.
69. Saito A, Suzuki Y, Ogata S, Ohtsuki C, Tanihara M. Prolonged ectopic calcification induced by BMP-2-derived synthetic peptide. J Biomed Mater Res 2004;70(1):115–121.
70. Duan Z, Zheng Q, Guo X, Yuan Q, Chen S. Experimental research on ectopic osteogenesis of BMP2-derived peptide P24 combined with PLGA copolymers. J Huazhong Univ Sci Technol 2007;27(2):179–182.
71. Yuan Q, Guo X, Zheng Q, Zhao M, Pan Z, Chen S, Quan D. Bioinspired growth of hydroxyapatite nanocrystals on PLGA-(PEG-ASP)n scaffolds modified with oligopeptide derived from BMP-2. Key Eng Mater 2007;334-335:1261–1264.
72. Wu B, Zheng Q, Guo X, Wu Y, Wang Y, Cui F. Preparation and ectopic osteogenesis in vivo of scaffold based on mineralized recombinant human-like collagen loaded with synthetic BMP-2-derived peptide. Biomed Mater 2008;3(4):044111.
73. Karp JM, Shoichet MS, Davies JE. Bone formation on two-dimensional poly(DL-lactide-co-glycolide) (PLGA) films and three-dimensional PLGA tissue engineering scaffolds in vitro. J Biomed Mater Res A 2003;64(2):388–396.
74. Lin ZY, Duan ZX, Guo XD, Li JF, Lu HW, Zheng QX, Quan DP, Yang SH. Bone induction by biomimetic PLGA-(PEG-ASP)n copolymer loaded with a novel synthetic BMP-2-related peptide in vitro and in vivo. J Control Release 2010;144(2):190–195.
75. Li J, Hong J, Zheng Q, Guo X, Lan S, Cui F, Pan H, Zou Z, Chen C. Repair of rat cranial bone defects with nHAC/PLLA and BMP-2-related peptide or rhBMP-2. J Orthop Res 2011;29(11):1745–1752.
76. Pountos I, Georgouli T, Henshaw K, Bird H, Jones E, Giannoudis PV. The effect of bone morphogenetic protein-2, bone morphogenetic protein-7, parathyroid hormone, and platelet-derived growth factor on the proliferation and osteogenic differentiation of mesenchymal stem cells derived from osteoporotic bone. J Orthop Trauma 2010;24(9):552–556.
77. Kim HK, Kim JH, Park DS, Park KS, Kang SS, Lee JS, Jeong MH, Yoon TR. Osteogenesis induced by a bone forming peptide from the prodomain region of BMP-7. Biomaterials 2012;33(29):7057–7063.
78. Chen Y, Webster TJ. Increased osteoblast functions in the presence of BMP-7 short peptides for nanostructured biomaterial applications. J Biomed Mater Res 2009;91(1):296–304.
79. Kang Q, Sun MH, Cheng H, Peng Y, Montag AG, Deyrup AT, Jiang W, Luu HH, Luo J, Szatkowski JP, Vanichakarn P, Park JY, Li Y, Haydon RC, He TC. Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther 2004;11(17):1312–1320.
80. Bergeron E, Marquis ME, Chrétien I, Faucheux N. Differentiation of preosteoblasts using a delivery system with BMPs and bioactive glass microspheres. J Mater Sci Mater Med 2007;18(2):255–263.
81. Bergeron E, Senta H, Mailloux A, Park H, Lord E, Faucheux N. Murine preosteoblast differentiation induced by a peptide derived from bone morphogenetic proteins-9. Tissue Eng 2009;15(11):3341–3349.
82. Bergeron E, Leblanc E, Drevelle O, Giguere R, Beauvais S, Grenier G, Faucheux N. The evaluation of ectopic bone formation induced by delivery systems for bone morphogenetic protein-9 or its derived peptide. Tissue Eng 2012;18(3-4):342–352.
83. Choi YJ, Lee JY, Park JH, Park JB, Suh JS, Choi YS, Lee SJ, Chung CP, Park YJ. The identification of a heparin binding domain peptide from bone morphogenetic protein-4 and its role on osteogenesis. Biomaterials 2010;31(28):7226–7238.
84. Chihara K, Sugimoto T. The action of GH/IGF-I/IGFBP in osteoblasts and osteoclasts. Horm Res 1997;5:45–49.
85. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008;29(5):535–559.
86. Kassem M, Blum W, Ristelli J, Mosekilde L, Eriksen EF. Growth hormone stimulates proliferation and differentiation of normal human osteoblast-like cells in vitro. Calcified Tissue Int 1993;52(3):222–226.
87. Canalis E, Economides AN, Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 2003;24(2):218–235.
88. Gillberg P, Mallmin H, Petren-Mallmin M, Ljunghall S, Nilsson AG. Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. J Clin Endocrinol Metab 2002;87(11):4900–4906.
89. Landin-Wilhelmsen K, Nilsson A, Bosaeus I, Bengtsson BA. Growth hormone increases bone mineral content in postmenopausal osteoporosis: A randomized placebo-controlled trial. J Bone Miner Res 2003;18(3):393–405.
90. Wuster C, Abs R, Bengtsson BA, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E, Monson JP, Westberg B, Wilton P. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 2001;16(2):398–405.
91. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402(6762):656–660.
92. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DG, Ghatei MA, Bloom SR. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000;141(11):4325–4328.
93. Kirchner H, Heppner KM, Tschop MH. The role of ghrelin in the control of energy balance. Handb Exp Pharmacol 2012;209:161–184.
94. Delhanty PJ, Neggers SJ, van der Lely AJ. Mechanisms in endocrinology: Ghrelin: The differences between acyl- and des-acyl ghrelin. Eur J Endocrinol 2012;167(5):601–608.
95. Depoortere I. Targeting the ghrelin receptor to regulate food intake. Regul Peptides 2009;156(1–3):13–23.
96. Ma C, Fukuda T, Ochi H, Sunamura S, Xu C, Xu R, Okawa A, Takeda S. Genetic determination of the cellular basis of the ghrelin-dependent bone remodeling. Mol Metab 2015;4(3):175–185.
97. Kim SW, Her SJ, Park SJ, Kim D, Park KS, Lee HK, Han BH, Kim MS, Shin CS, Kim SY. Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells. Bone 2005;37(3):359–369.
98. Nanzer AM, Khalaf S, Mozid AM, Fowkes RC, Patel MV, Burrin JM, Grossman AB, Korbonits M. Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway. Eur J Endocrinol 2004;151(2):233–240.
99. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, Malan D, Baj G, Granata R, Broglio F, Papotti M, Surico N, Bussolino F, Isgaard J, Deghenghi R, Sinigaglia F, Prat M, Muccioli G, Ghigo E, Graziani A. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 2002;159(6):1029–1037.
100. Mrak E, Casati L, Pagani F, Rubinacci A, Zarattini G, Sibilia V. Ghrelin increases beta-catenin level through protein kinase A activation and regulates OPG expression in rat primary osteoblasts. Int J Endocrinol 2015;2015:10.
101. Liang QH, Liu Y, Wu SS, Cui RR, Yuan LQ, Liao EY. Ghrelin inhibits the apoptosis of MC3T3-E1 cells through ERK and AKT signaling pathway. Toxicol Appl Pharmacol 2013;272(3):591–597.
102. Fukushima N, Hanada R, Teranishi H, Fukue Y, Tachibana T, Ishikawa H, Takeda S, Takeuchi Y, Fukumoto S, Kangawa K, Nagata K, Kojima M. Ghrelin directly regulates bone formation. J Bone Miner Res 2005;20(5):790–798.
103. Choi HJ, Ki KH, Yang JY, Jang BY, Song JA, Baek WY, Kim JH, An JH, Kim SW, Kim SY, Kim JE, Shin CS. Chronic central administration of ghrelin increases bone mass through a mechanism independent of appetite regulation. PLoS One 2013;8(7):e65505.
104. Amini P, Cahill F, Wadden D, Ji Y, Pedram P, Vidyasankar S, Yi Y, Gulliver W, Paterno G, Zhang H, Rideout A, Sun G. Beneficial association of serum ghrelin and peptide YY with bone mineral density in the Newfoundland population. BMC Endocr Disord 2013;13(35):1472–6823.
105. Gonnelli S, Caffarelli C, Del Santo K, Cadirni A, Guerriero C, Lucani B, Franci B, Nuti R. The relationship of ghrelin and adiponectin with bone mineral density and bone turnover markers in elderly men. Calcif Tissue Int 2008;83(1):55–60.
106. Huda M, Durham B, Wong S, Dovey T, McCulloch P, Kerrigan D, Pinkney J, Fraser W, Wilding J. Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects. Bone 2007;41(3):406–413.
107. Deng F, Ling J, Ma J, Liu C, Zhang W. Stimulation of intramembranous bone repair in rats by ghrelin. Exp Physiol 2008;93(7):872–879.
108. Costa JL, Naot D, Lin J-M, Watson M, Callon KE, Reid IR, Grey AB, Cornish J. Ghrelin is an osteoblast mitogen and increases osteoclastic bone resorption in vitro. Int J Pept 2011;2011:1–7.
109. Delhanty PJ, van der Eerden BC, van der Velde M, Gauna C, Pols HA, Jahr H, Chiba H, van der Lely AJ, van Leeuwen JP. Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a. J Endocrinol 2006;188(1):37–47.
110. Bednarek MA, Feighner SD, Pong SS, McKee KK, Hreniuk DL, Silva MV, Warren VA, Howard AD, Van Der Ploeg LH, Heck JV. Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J Med Chem 2000;43(23):4370–4376.
111. Matsumoto M, Hosoda H, Kitajima Y, Morozumi N, Minamitake Y, Tanaka S, Matsuo H, Kojima M, Hayashi Y, Kangawa K. Structure-activity relationship of ghrelin: pharmacological study of ghrelin peptides. Biochem Biophys Res Commun 2001;287(1):142–146.
112. Morozumi N, Hanada T, Habara H, Yamaki A, Furuya M, Nakatsuka T, Inomata N, Minamitake Y, Ohsuye K, Kangawa K. The role of C-terminal part of ghrelin in pharmacokinetic profile and biological activity in rats. Peptides 2011;32(5):1001–1007.
113. Van Craenenbroeck M, Gregoire F, De Neef P, Robberecht P, Perret J. Ala-scan of ghrelin (1-14): Interaction with the recombinant human ghrelin receptor. Peptides 2004;25(6):959–965.
114. Maletínská L, Pýchová M, Holubová M, Blechová M, Demianová Z, Elbert T, Železná B. Characterization of new stable ghrelin analogs with prolonged orexigenic potency. J Pharmacol Exp Ther 2012;340(3):781–786.
115. Sibilia V, Cocchi D, Pagani F, Lattuada N, Moro GL, Pecile A, Rubinacci A, Muller EE, Netti C. Hexarelin, a growth hormone-releasing peptide, counteracts bone loss in gonadectomized male rats. Growth Horm IGF Res 1999;9(4):219–227.
116. Cella SG, Cerri CG, Daniel S, Sibilia V, Rigamonti A, Cattaneo L, Deghenghi R, Muller EE. Sixteen weeks of hexarelin therapy in aged dogs: Effects on the somatotropic axis, muscle morphology, and bone metabolism. J Gerontol A Biol Sci Med Sci 1996;51(6):B439–B447.
117. Maccarinelli G, Sibilia V, Torsello A, Raimondo F, Pitto M, Giustina A, Netti C, Cocchi D. Ghrelin regulates proliferation and differentiation of osteoblastic cells. J Endocrinol 2005;184(1):249–256.
118. Thomas A, Delahaut P, Krug O, Schanzer W, Thevis M. Metabolism of growth hormone releasing peptides. Anal Chem 2012;84(23):10252–10259.
119. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res 1999;9(2):106–113.
120. Svensson J, Lall S, Dickson SL, Bengtsson BA, Romer J, Ahnfelt-Ronne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol 2000;165(3):569–577.
121. Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139(5):552–561.
122. Naot D, Cornish J. Cytokines and hormones that contribute to the positive association between fat and bone. Front Endocrinol 2014;5(70):1–9.
123. Kahn SE, D'Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, Taborsky GJ, Porte D. Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 1990;39(5):634–638.
124. Cooper G, Willis A, Clark A, Turner R, Sim R, Reid K. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 1987;84:8628–8632.
125. Cooper GJS. Amylin compared with calcitonin gene-related peptide: Structure, biology, and relevance to metabolic disease. Endocr Rev 1994;15(2):163–201.
126. Alam A, Moonga B, Bevis P, Huang C, Zaidi M. Amylin inhibits bone resorption by a direct effect on the motility of rat osteoclasts. Exp Physiol 1993;78(2):183–196.
127. Macintyre I. Amylinamide, bone conservation, and pancreatic beta cells. Lancet 1989;334(8670):1026–1027.
128. Pietschmann P, Farsoudi KH, Hoffmann O, Klaushofer K, Hörandner H, Peterlik M. Inhibitory effect of amylin on basal and parathyroid hormone-stimulated bone resorption in cultured neonatal mouse calvaria. Bone 1993;14(2):167–172.
129. Cornish J, Naot D. Amylin and adrenomedullin: Novel regulators of bone growth. Curr Pharm Des 2002;8(23):2009–2021.
130. Cornish J, Callon KE, Cooper GJS, Reid IR. Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. Biochem Biophys Res Commun 1995;207(1):133–139.
131. Villa I, Rubinacci A, Ravasi F, Ferrara AF, Guidobono F. Effects of amylin on human osteoblast-like cells. Peptides 1997;18(4):537–540.
132. Burns MD, Kawase T. Calcitonin-gene related peptide, amylin, or parathyroid hormone stimulate (in vitro) biomineralization (Abstract). J Bone Miner Res 1997;12:392.
133. Cornish J, Callon KE, Lin CQ-X, Xiao CL, Mulvey TB, Coy DH, Cooper GJS, Reid IR. Dissociation of the effects of amylin on osteoblast proliferation and bone resorption. Am J Physiol 1998;274(5):827–833.
134. Cornish J, Callon KE, King AR, Cooper GJS, Reid IR. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am J Physiol 1998;275(4):694–699.
135. Horcajada-Molteni M-N, Chanteranne B, Lebecque P, Davicco M-J, Coxam V, Young A, Barlet J-P. Amylin and bone metabolism in streptozotocin-induced diabetic rats. J Bone Miner Res 2001;16(5):958–965.
136. Bronský J, Průša R. Amylin fasting plasma levels are decreased in patients with osteoporosis. Osteoporos Int 2004;15(3):243–247.
137. Wojcik MH, Meenaghan E, Lawson EA, Misra M, Klibanski A, Miller KK. Reduced amylin levels are associated with low bone mineral density in women with anorexia nervosa. Bone 2010;46(3):796–800.
138. Cornish J, Callon KE, Gasser JA, Bava U, Gardiner EM, Coy DH, Cooper GJS, Reid IR. Systemic administration of a novel octapeptide, amylin-(1–8), increases bone volume in male mice. Am J Physiol Endocrinol Metab 2000;279(4):E730–E735.
139. Ellegaard M, Thorkildsen C, Petersen S, Petersen J, Jørgensen N, Just R, Schwarz P, Ramirez M, Stahlhut M. Amylin(1–8) is devoid of anabolic activity in bone. Calcified Tissue Int 2010;86(3):249–260.
140. Kowalczyk R, Harris PWR, Brimble MA, Callon KE, Watson M, Cornish J. Synthesis and evaluation of disulfide bond mimetics of amylin-(1–8) as agents to treat osteoporosis. Bioorg Med Chem 2012;20(8):2661–2668.
141. Kowalczyk R, Brimble MA, Callon KE, Watson M, Cornish J. How to blast osteoblasts? Novel dicarba analogues of amylin-(1–8) to treat osteoporosis. Bioorg Med Chem 2012;20(20):6011–6018.
142. Buchanan C, Phillips A, Cooper G. Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet beta-cells and enhances insulin secretion. Biochem J 2001;360:431–439.
143. Buchanan CM, Peng Z, Cefre A, Sarojini V. Preptin analogues: Chemical synthesis, secondary structure and biological studies. Chem Biol Drug Des 2013;82(4):429–437.
144. Khosla S, Ballard FJ, Conover CA. Use of site-specific antibodies to characterize the circulating form of big insulin-like growth factor II in patients with hepatitis C-associated osteosclerosis. J Clin Endocr Metab 2002;87(8):3867–3870.
145. Li N, Zheng Y-B, Han J, Liang W, Wang J-Y, Zhou J-R, Shen Y, Zhang J. Lower circulating preptin levels in male patients with osteoporosis are correlated with bone mineral density and bone formation. BMC Musculoskel Dis 2013;14(1):49.
146. Cornish J, Callon KE, Bava U, Watson M, Xu X, Lin JM, Chan VA, Grey AB, Naot D, Buchanan CM, Cooper GJ, Reid IR. Preptin, another peptide product of the pancreatic beta-cell, is osteogenic in vitro and in vivo. Am J Physiol Endocrinol Metab 2007;292(1):15.
147. Cornish J, Reid, I. Preptin fragments and methods of use. US Patent Application US20070173456 A1. 2007.
148. Bosetti M, Sabbatini M, Nicolì E, Fusaro L, Cannas M. Effects and differentiation activity of IGF-I, IGF-II, insulin and preptin on human primary bone cells. Growth Factors 2013;31(2):57–65.
149. Liu Y, Lu Y, Liu W, Xie H, Luo X, Wu X, Yuan L, Liao E. Connective tissue growth factor is a downstream mediator for preptin-induced proliferation and differentiation in human osteoblasts. Amino Acids 2010;38:763–769.
150. Buchanan CM, Cooper GJ. Peptide having Preptin Functionality. PCT International Application WO 2000078805 A1. 2000.
151. Amso Z, Kowalczyk R, Park Y-E, Watson M, Callon KE, Cornish J, Brimble MA. Structure activity relationship (SAR) study on the peptide hormone preptin, a novel anabolic agent for the treatment of osteoporosis. School of Chemical Sciences. Auckland, New Zealand: The University of Auckland; 2016.
152. Amso Z, Kowalczyk R, Park Y-E, Cornish J, Brimble MA. Synthesis and in vitro osteoblast proliferative activity of cyclic preptin analogues. School of Chemical Sciences. Auckland, New Zealand: The University of Auckland; 2016.
153. Kowalczyk R, Yang SH, Brimble MA, Callon KE, Watson M, Park Y-E, Cornish J. Synthesis of truncated analogues of preptin-(1–16), and investigation of their ability to stimulate osteoblast proliferation. Bioorg Med Chem 2014;22(14):3565–3572.
154. Licinio-Paixao J, Polonsky KS, Given BD, Pugh W, Ostrega D, Frank BF, Rubenstein AH. Ingestion of a mixed meal does not affect the metabolic clearance rate of biosynthetic human C-peptide. J Clin Endocrinol Metab 1986;63(2):401–403.
155. Lopez-Ibarra PJ, Pastor MM, Escobar-Jimenez F, Pardo MD, Gonzalez AG, Luna JD, Requena ME, Diosdado MA. Bone mineral density at time of clinical diagnosis of adult-onset type 1 diabetes mellitus. Endocr Pract 2001;7(5):346–351.
156. Li Y, Liu H, Sato Y. The association between the serum C-peptide level and bone mineral density. PLoS One 2013;8(12):e83107.
157. Montalcini T, Gallotti P, Coppola A, Zambianchi V, Fodaro M, Galliera E, Marazzi MG, Romeo S, Giannini S, Corsi Romanelli MM, Pujia A, Gazzaruso C. Association between low C-peptide and low lumbar bone mineral density in postmenopausal women without diabetes. Osteoporos Int 2015;26(5):1639–1646.
158. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): A new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990;168(2):863–870.
159. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006;27(1):47–72.
160. Vollmar AM, Gerbes AL, Nemer M, Schulz R. Detection of C-type natriuretic peptide (CNP) transcript in the rat heart and immune organs. Endocrinology 1993;132(4):1872–1874.
161. Suga S, Nakao K, Itoh H, Komatsu Y, Ogawa Y, Hama N, Imura H. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of “vascular natriuretic peptide system.” J Clin Invest 1992;90(3):1145–1149.
162. Komatsu Y, Chusho H, Tamura N, Yasoda A, Miyazawa T, Suda M, Miura M, Ogawa Y, Nakao K. Significance of C-type natriuretic peptide (CNP) in endochondral ossification: analysis of CNP knockout mice. J Bone Miner Metab 2002;20(6):331–336.
163. Inoue A, Hayakawa T, Otsuka E, Kamiya A, Suzuki Y, Hirose S, Hagiwara H. Correlation between induction of expression of biglycan and mineralization by C-type natriuretic peptide in osteoblastic cells. J Biochem 1999;125(1):103–108.
164. Holliday LS, Dean AD, Greenwald JE, Glucks SL. C-type natriuretic peptide increases bone resorption in 1,25-dihydroxyvitamin D3-stimulated mouse bone marrow cultures. J Biol Chem 1995;270(32):18983–18989.
165. Inoue A, Otsuka E, Hiruma Y, Hirose S, Furuya M, Tanaka S, Hagiwara H. Stimulation by retinoids of the natriuretic peptide system of osteoblastic MC3T3-E1 cells. Biochem Biophys Res Commun 1996;228(1):182–186.
166. Inoue A, Hiruma Y, Hirose S, Yamaguchi A, Furuya M, Tanaka S, Hagiwara H. Stimulation by C-type natriuretic peptide of the differentiation of clonal osteoblastic MC3T3-E1 cells. Biochem Biophys Res Commun 1996;221(3):703–707.
167. Lenz A, Bennett M, Skelton WPt, Vesely DL. Vessel dilator and C-type natriuretic peptide enhance the proliferation of human osteoblasts. Pediatr Res 2010;68(5):405–408.
168. Yeh LC, Zavala MC, Lee JC. C-type natriuretic peptide enhances osteogenic protein-1-induced osteoblastic cell differentiation via Smad5 phosphorylation. J Cell Biochem 2006;97(3):494–500.
169. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000;1(3):169–178.
170. Kondo E, Yasoda A, Fujii T, Nakao K, Yamashita Y, Ueda-Sakane Y, Kanamoto N, Miura M, Arai H, Mukoyama M, Inagaki N. Increased bone turnover and possible accelerated fracture healing in a murine model with an increased circulating C-type natriuretic peptide. Endocrinology 2015;156(7):2518–2529.
171. Kaneki H, Kurokawa M, Ide H. The receptor attributable to C-type natriuretic peptide-induced differentiation of osteoblasts is switched from type B- to type C-natriuretic peptide receptor with aging. J Cell Biochem 2008;103(3):753–764.
172. Agoston H, Khan S, James CG, Gillespie JR, Serra R, Stanton LA, Beier F. C-type natriuretic peptide regulates endochondral bone growth through p38 MAP kinase-dependent and -independent pathways. BMC Dev Biol 2007;7:18.
173. Yasoda A, Komatsu Y, Chusho H, Miyazawa T, Ozasa A, Miura M, Kurihara T, Rogi T, Tanaka S, Suda M, Tamura N, Ogawa Y, Nakao K. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med 2004;10(1):80–86.
174. Chusho H, Tamura N, Ogawa Y, Yasoda A, Suda M, Miyazawa T, Nakamura K, Nakao K, Kurihara T, Komatsu Y, Itoh H, Tanaka K, Saito Y, Katsuki M. Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci USA 2001;98(7):4016–4021.
175. Kondo E, Yasoda A, Tsuji T, Fujii T, Miura M, Kanamoto N, Tamura N, Arai H, Kunieda T, Nakao K. Skeletal analysis of the long bone abnormality (lbab/lbab) mouse, a novel chondrodysplastic C-type natriuretic peptide mutant. Calcif Tissue Int 2012;90(4):307–318.
176. Waldman SD, Usmani Y, Tse MY, Pang SC. Differential effects of natriuretic peptide stimulation on tissue-engineered cartilage. Tissue Eng 2008;14(3):441–448.
177. Krejci P, Masri B, Fontaine V, Mekikian PB, Weis M, Prats H, Wilcox WR. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J Cell Sci 2005;118(Pt 21):5089–5100.
178. Brandt RR, Heublein DM, Aarhus LL, Lewicki JA, Burnett JC, Jr. Role of natriuretic peptide clearance receptor in in vivo control of C-type natriuretic peptide. Am J Physiol 1995;269(1 Pt 2):H326–H331.
179. Brandt RR, Mattingly MT, Clavell AL, Barclay PL, Burnett JC, Jr. Neutral endopeptidase regulates C-type natriuretic peptide metabolism but does not potentiate its bioactivity in vivo. Hypertension 1997;30(2 Pt 1):184–190.
180. Yasoda A, Kitamura H, Fujii T, Kondo E, Murao N, Miura M, Kanamoto N, Komatsu Y, Arai H, Nakao K. Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias. Endocrinology 2009;150(7):3138–3144.
181. Shaikh N, Russo L, Papaleo E, Giannoni P, De Gioia L, Nicotra F, Quarto R, Cipolla L. C-type natriuretic peptide: Structural studies, fragment synthesis, and preliminary biological evaluation in human osteosarcoma cell lines. Biopolymers 2010;94(2):213–219.
182. Wendt DJ, Dvorak-Ewell M, Bullens S, Lorget F, Bell SM, Peng J, Castillo S, Aoyagi-Scharber M, O'Neill CA, Krejci P, Wilcox WR, Rimoin DL, Bunting S. Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism. J Pharmacol Exp Ther 2015;353(1):132–149.
183. Lorget F, Kaci N, Peng J, Benoist-Lasselin C, Mugniery E, Oppeneer T, Wendt DJ, Bell SM, Bullens S, Bunting S, Tsuruda LS, O'Neill CA, Di Rocco F, Munnich A, Legeai-Mallet L. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet 2012;91(6):1108–1114.
184. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332(6163):411–415.
185. Damon DH. Endothelin and post-ganglionic sympathetic neurons. Clin Exp Pharmacol Physiol 1999;26(12):1000–1003.
186. Kitten AM, Andrews CJ. Endothelin-1 expression in long-term cultures of fetal rat calvarial osteoblasts: Regulation by BMP-7. J Cell Physiol 2001;187(2):218–225.
187. Kitano Y, Kurihara H, Kurihara Y, Maemura K, Ryo Y, Yazaki Y, Harii K. Gene expression of bone matrix proteins and endothelin receptors in endothelin-1-deficient mice revealed by in situ hybridization. J Bone Miner Res 1998;13(2):237–244.
188. Shioide M, Noda M. Endothelin modulates osteopontin and osteocalcin messenger ribonucleic acid expression in rat osteoblastic osteosarcoma cells. J Cell Biochem 1993;53(2):176–180.
189. Tatrai A, Foster S, Lakatos P, Shankar G, Stern PH. Endothelin-1 actions on resorption, collagen and noncollagen protein synthesis, and phosphatidylinositol turnover in bone organ cultures. Endocrinology 1992;131(2):603–607.
190. Suzuki A, Shinoda J, Watanabe-Tomita Y, Ozaki N, Oiso Y, Kozawa O. ETA receptor mediates the signaling of endothelin-1 in osteoblast-like cells. Bone 1997;21(2):143–146.
191. von Schroeder HP, Veillette CJ, Payandeh J, Qureshi A, Heersche JN. Endothelin-1 promotes osteoprogenitor proliferation and differentiation in fetal rat calvarial cell cultures. Bone 2003;33(4):673–684.
192. Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy JD, Jr., Fox JW, Chirgwin JM, Guise TA. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol 2007;21(2):486–498.
193. Van Sant C, Wang G, Anderson MG, Trask OJ, Lesniewski R, Semizarov D. Endothelin signaling in osteoblasts: Global genome view and implication of the calcineurin/NFAT pathway. Mol Cancer Ther 2007;6(1):253–261.
194. Hiruma Y, Inoue A, Shiohama A, Otsuka E, Hirose S, Yamaguchi A, Hagiwara H. Endothelins inhibit the mineralization of osteoblastic MC3T3-E1 cells through the A-type endothelin receptor. Am J Physiol 1998;275(4 Pt 2):R1099–R1105.
195. Gulhan I, Kebapcilar L, Alacacioglu A, Bilgili S, Kume T, Aytac B, Gunaydin R. Postmenopausal women with osteoporosis may be associated with high endothelin-1. Gynecol Endocrinol 2009;25(10):674–678.
196. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1(9):944–949.
197. Lundberg P, Lerner UH. Expression and regulatory role of receptors for vasoactive intestinal peptide in bone cells. Microsc Res Tech 2002;58(2):98–103.
198. Chenu C, Marenzana M. Sympathetic nervous system and bone remodeling. Joint Bone Spine 2005;72:481–483.
199. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 1989;164(1):567–574.
200. Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, Fournier A, Chow BK, Hashimoto H, Galas L, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 Years after the discovery. Pharmacol Rev 2009;61(3):283–357.
201. Cai Y, Xin X, Shim G-J, Mokuno Y, Uehara H, Yamada T, Agui T, Matsumoto K. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells. Endocrinology 1997;138(6):2515–2520.
202. Gonkowski S, Calka J. Changes in pituitary adenylate cyclase-activating peptide 27-like immunoreactive nervous structures in the porcine descending colon during selected pathological processes. J Mol Neurosci 2012;48(3):777–787.
203. Lundberg P, Lundgren I, Mukohyama H, Lehenkari PP, Horton MA, Lerner UH. Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide receptor subtypes in mouse calvarial osteoblasts: Presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors 1. Endocrinology 2001;142(1):339–347.
204. Suzuki A, Kotoyori J, Oiso Y, Kozawa O. Pituitary adenylate cyclase-activating polypeptide induces cAMP production independently from vasoactive intestinal polypeptide in osteoblast-like cells. Cell Signal 1994;6(1):11–16.
205. Juhasz T, Matta C, Katona E, Somogyi C, Takacs R, Hajdu T, Helgadottir SL, Fodor J, Csernoch L, Toth G, Bako E, Reglodi D, Tamas A, Zakany R. Pituitary adenylate cyclase-activating polypeptide (PACAP) signalling enhances osteogenesis in UMR-106 cell line. J Mol Neurosci 2014;54(3):555–573.
206. Hohmann EL, Elde RP, Rysavy JA, Einzig S, Gebhard RL. Innervation of periosteum and bone by sympathetic vasoactive intestinal peptide-containing nerve fibers. Science 1986;232(4752):868–871.
207. Strange-Vognsen HH, Arnbjerg J, Hannibal J. Immunocytochemical demonstration of pituitary adenylate cyclase activating polypeptide (PACAP) in the porcine epiphyseal cartilage canals. Neuropeptides 1997;31(2):137–141.
208. Lundberg P, Bostrom I, Mukohyama H, Bjurholm A, Smans K, Lerner UH. Neuro-hormonal control of bone metabolism: Vasoactive intestinal peptide stimulates alkaline phosphatase activity and mRNA expression in mouse calvarial osteoblasts as well as calcium accumulation mineralized bone nodules. Regul Pept 1999;85(1):47–58.
209. Ma WH, Liu YJ, Wang W, Zhang YZ. Neuropeptide Y, substance P, and human bone morphogenetic protein 2 stimulate human osteoblast osteogenic activity by enhancing gap junction intercellular communication. Braz J Med Biol Res 2015;48(4):299–307.
210. Ma W, Zhang X, Shi S, Zhang Y. Neuropeptides stimulate human osteoblast activity and promote gap junctional intercellular communication. Neuropeptides 2013;47(3):179–186.
211. Nagata A, Tanaka T, Minezawa A, Poyurovsky M, Mayama T, Suzuki S, Hashimoto N, Yoshida T, Suyama K, Miyata A, Hosokawa H, Nakayama T, Tatsuno I. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells. J Cell Physiol 2009;221(1):75–83.
212. Persson E, Lerner UH. The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts. J Cell Biochem 2011;112(12):3732–3741.
213. Winding B, Wiltink A, Foged NT. Pituitary adenylyl cyclase-activating polypeptides and vasoactive intestinal peptide inhibit bone resorption by isolated rabbit osteoclasts. Exp Physiol 1997;82(5):871–886.
214. Mukohyama H, Ransjo M, Taniguchi H, Ohyama T, Lerner UH. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. Biochem Biophys Res Commun 2000;271(1):158–163.
215. Ding WG, Zhang ZM, Zhang YH, Jiang SD, Jiang LS, Dai LY. Changes of substance P during fracture healing in ovariectomized mice. Regul Pept 2010;159(1–3):28–34.
216. Azuma H, Kido J, Ikedo D, Kataoka M, Nagata T. Substance P enhances the inhibition of osteoblastic cell differentiation induced by lipopolysaccharide from Porphyromonas gingivalis. J Periodontol 2004;75(7):974–981.
217. Goto T, Nakao K, Gunjigake KK, Kido MA, Kobayashi S, Tanaka T. Substance P stimulates late-stage rat osteoblastic bone formation through neurokinin-1 receptors. Neuropeptides 2007;41(1):25–31.
218. Mei G, Zou Z, Fu S, Xia L, Zhou J, Zhang Y, Tuo Y, Wang Z, Jin D. Substance P activates the Wnt signal transduction pathway and enhances the differentiation of mouse preosteoblastic MC3T3-E1 cells. Int J Mol Sci 2014;15(4):6224–6240.
219. Fu S, Mei G, Wang Z, Zou Z-L, Liu S, Pei G-X, Bi L, Jin D. Neuropeptide substance P improves osteoblastic and angiogenic differentiation capacity of bone marrow stem cells in vitro. BioMed Res Int 2014;2014:10.
220. Fu S, Jin D, Liu S, Wang L, Wang Z, Mei G, Zou ZL, Wu JQ, Xu ZY. Protective effect of neuropeptide substance P on bone marrow mesenchymal stem cells against apoptosis induced by serum deprivation. Stem Cells Int 2015;270328(10):28.
221. Adamus MA, Dabrowski ZJ. Effect of the neuropeptide substance P on the rat bone marrow-derived osteogenic cells in vitro. J Cell Biochem 2001;81(3):499–506.
222. Wang L, Zhao R, Shi X, Wei T, Halloran BP, Clark DJ, Jacobs CR, Kingery WS. Substance P stimulates bone marrow stromal cell osteogenic activity, osteoclast differentiation, and resorption activity in vitro. Bone 2009;45(2):309–320.
223. Wrobel E, Leszczynska J, Przybylski J. [Role of Gap junctions in bone tissue]. Postepy Biochem 2011;57(4):411–417.
224. Hong HS, Um J, Lee ZH, Son Y. Long-term comparative study of substance-P with methylprednisolone on the development of osteoporosis. J Toxicol Sci 2014;39(3):391–399.
225. Hong H, Lim S, Son Y. Evaluation of substance-P toxicity with single dose and repeated dose in rats. Mol Cell Toxicol 2015;11(2):201–211.
226. Evans HF, Shine J. Human galanin: Molecular cloning reveals a unique structure. Endocrinology 1991;129(3):1682–1684.
227. Branchek TA, Smith KE, Gerald C, Walker MW. Galanin receptor subtypes. Trends Pharmacol Sci 2000;21(3):109–117.
228. Mahoney SA, Hosking R, Farrant S, Holmes FE, Jacoby AS, Shine J, Iismaa TP, Scott MK, Schmidt R, Wynick D. The second galanin receptor GalR2 plays a key role in neurite outgrowth from adult sensory neurons. J Neurosci 2003;23(2):416–421.
229. Ji R-R, Zhang X, Zhang Q, Dagerlind Å, Nilsson S, Wiesenfeld-Hallin Z, Hökfelt T. Central and peripheral expression of galanin in response to inflammation. Neuroscience 1995;68(2):563–576.
230. Xu ZQ, Shi TJ, Hokfelt T. Expression of galanin and a galanin receptor in several sensory systems and bone anlage of rat embryos. Proc Natl Acad Sci USA 1996;93(25):14901–14905.
231. Jones M, Perumal P, Vrontakis M. Presence of galanin-like immunoreactivity in mesenchymal and neural crest origin tissues during embryonic development in the mouse. Anat Rec 2009;292(4):481–487.
232. McDonald AC, Schuijers JA, Shen P-J, Gundlach AL, Grills BL. Expression of galanin and galanin receptor-1 in normal bone and during fracture repair in the rat. Bone 2003;33(5):788–797.
233. McDonald A, Schuijers J, Gundlach A, Grills B. Galanin treatment offsets the inhibition of bone formation and downregulates the increase in mouse calvarial expression of TNFα and GalR2 mRNA induced by chronic daily injections of an injurious vehicle. Bone 2007;40(4):895–903.
234. Sakurai T, Mieda M. Connectomics of orexin-producing neurons: Interface of systems of emotion, energy homeostasis and arousal. Trends Pharmacol Sci 2011;32(8):451–462.
235. Sakurai T. The neural circuit of orexin (hypocretin): Maintaining sleep and wakefulness. Nat Rev Neurosci 2007;8(3):171–181.
236. Wei W, Motoike T, Krzeszinski JY, Jin Z, Xie XJ, Dechow PC, Yanagisawa M, Wan Y. Orexin regulates bone remodeling via a dominant positive central action and a subordinate negative peripheral action. Cell Metab 2014;19(6):927–940.
237. Ziolkowska A, Rucinski M, Tyczewska M, Malendowicz LK. Orexin B inhibits proliferation and stimulates specialized function of cultured rat calvarial osteoblast-like cells. Int J Mol Med 2008;22(6):749–755.
238. Lang M, Söll RM, Dürrenberger F, Dautzenberg FM, Beck-Sickinger AG. Structure−activity studies of orexin A and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands. J Med Chem 2004;47(5):1153–1160.
239. Green J, Schotland S, Stauber DJ, Kleeman CR, Clemens TL. Cell-matrix interaction in bone: type I collagen modulates signal transduction in osteoblast-like cells. Am J Physiol 1995;268(5 Pt 1):C1090–C1103.
240. Qian JJ, Bhatnagar RS. Enhanced cell attachment to anorganic bone mineral in the presence of a synthetic peptide related to collagen. J Biomed Mater Res 1996;31(4):545–554.
241. Bhatnagar RS, Qian JJ, Wedrychowska A, Sadeghi M, Wu YM, Smith N. Design of biomimetic habitats for tissue engineering with P-15, a synthetic peptide analogue of collagen. Tissue Eng 1999;5(1):53–65.
242. Nguyen H, Qian JJ, Bhatnagar RS, Li S. Enhanced cell attachment and osteoblastic activity by P-15 peptide-coated matrix in hydrogels. Biochem Biophys Res Commun 2003;311(1):179–186.
243. Thorwarth M, Schultze-Mosgau S, Wehrhan F, Kessler P, Srour S, Wiltfang J, Andreas Schlegel K. Bioactivation of an anorganic bone matrix by P-15 peptide for the promotion of early bone formation. Biomaterials 2005;26(28):5648–5657.
244. Artzi Z, Kozlovsky A, Nemcovsky CE, Moses O, Tal H, Rohrer MD, Prasad HS, Weinreb M. Histomorphometric evaluation of natural mineral combined with a synthetic cell-binding peptide (P-15) in critical-size defects in the rat calvaria. Int J Oral Maxillofac Implants 2008;23(6):1063–1070.
245. Hole BB, Schwarz JA, Gilbert JL, Atkinson BL. A study of biologically active peptide sequences (P-15) on the surface of an ABM scaffold (PepGen P-15) using AFM and FTIR. J Biomed Mater Res A 2005;74(4):712–721.
246. Bhongade ML, Tiwari IR. A comparative evaluation of the effectiveness of an anorganic bone matrix/cell binding peptide with an open flap debridement in human infrabony defects: A clinical and radiographic study. J Contemp Dent Pract 2007;8(6):25–34.
247. Gomar F, Orozco R, Villar JL, Arrizabalaga F. P-15 small peptide bone graft substitute in the treatment of non-unions and delayed union. A pilot clinical trial. Int Orthop 2007;31(1):93–99.
248. Hestehave Pedersen R, Rasmussen M, Overgaard S, Ding M. Effects of P-15 peptide coated hydroxyapatite on tibial defect repair in vivo in normal and osteoporotic rats. BioMed Res Int 2015;2015:1–14.
249. Thorwarth M, Schultze-Mosgau S, Wehrhan F, Srour S, Wiltfang J, Neukam FW, Schlegel KA. Enhanced bone regeneration with a synthetic cell-binding peptide—In vivo results. Biochem Biophys Res Commun 2005;329(2):789–795.
250. Park JB, Lee JY, Park HN, Seol YJ, Park YJ, Rhee SH, Lee SC, Kim KH, Kim TI, Lee YM, Ku Y, Rhyu IC, Han SB, Chung CP. Osteopromotion with synthetic oligopeptide-coated bovine bone mineral in vivo. J Periodontol 2007;78(1):157–163.
251. Yukna RA, Callan DP, Krauser JT, Evans GH, Aichelmann-Reidy ME, Moore K, Cruz R, Scott JB. Multi-center clinical evaluation of combination anorganic bovine-derived hydroxyapatite matrix (ABM)/cell binding peptide (P-15) as a bone replacement graft material in human periodontal osseous defects. 6-Month results. J Periodontol 1998;69(6):655–663.
252. Lee CK, Koo KT, Park YJ, Lee JY, Rhee SH, Ku Y, Rhyu IC, Chung CP. Biomimetic surface modification using synthetic oligopeptides for enhanced guided bone regeneration in beagles. J Periodontol 2012;83(1):101–110.
253. Wang V, Misra G, Amsden B. Immobilization of a bone and cartilage stimulating peptide to a synthetic bone graft. J Mater Sci Mater Med 2008;19(5):2145–2155.
254. Agrawal V, Tottey S, Johnson SA, Freund JM, Siu BF, Badylak SF. Recruitment of progenitor cells by an extracellular matrix cryptic peptide in a mouse model of digit amputation. Tissue Eng 2011;17(19–20):2435–2443.
255. Agrawal V, Kelly J, Tottey S, Daly KA, Johnson SA, Siu BF, Reing J, Badylak SF. An isolated cryptic peptide influences osteogenesis and bone remodeling in an adult mammalian model of digit amputation. Tissue Eng 2011;17(23–24):3033–3044.
256. Yamada S, Yoshizawa Y, Kawakubo A, Ikeda T, Yanagiguchi K, Hayashi Y. Early gene and protein expression associated with osteoblast differentiation in response to fish collagen peptides powder. Dent Mater J 2013;32(2):233–240.
257. Staatz WD, Fok KF, Zutter MM, Adams SP, Rodriguez BA, Santoro SA. Identification of a tetrapeptide recognition sequence for the alpha 2 beta 1 integrin in collagen. J Biol Chem 1991;266(12):7363–7367.
258. Yoo SY, Kobayashi M, Lee PP, Lee S-W. Early osteogenic differentiation of mouse preosteoblasts induced by collagen-derived DGEA-peptide on nanofibrous phage tissue matrices. Biomacromolecules 2011;12(4):987–996.
259. Hennessy KM, Pollot BE, Clem WC, Phipps MC, Sawyer AA, Culpepper BK, Bellis SL. The effect of collagen I mimetic peptides on mesenchymal stem cell adhesion and differentiation, and on bone formation at hydroxyapatite surfaces. Biomaterials 2009;30(10):1898–1909.
260. Mehta M, Madl CM, Lee S, Duda GN, Mooney DJ. The collagen I mimetic peptide DGEA enhances an osteogenic phenotype in mesenchymal stem cells when presented from cell-encapsulating hydrogels. J Biomed Mater Res A 2015;8(10):35497.
261. Baerts L, Glorie L, Maho W, Eelen A, Verhulst A, D'Haese P, Covaci A, De Meester I. Potential impact of sitagliptin on collagen-derived dipeptides in diabetic osteoporosis. Pharmacol Res 2015;100:336–340.
262. Kimira Y, Ogura K, Taniuchi Y, Kataoka A, Inoue N, Sugihara F, Nakatani S, Shimizu J, Wada M, Mano H. Collagen-derived dipeptide prolyl-hydroxyproline promotes differentiation of MC3T3-E1 osteoblastic cells. Biochem Biophys Res Commun 2014;453(3):498–501.
263. Lee J-Y, Choo J-E, Choi Y-S, Park J-B, Min D-S, Lee S-J, Rhyu HK, Jo I-H, Chung C-P, Park Y-J. Assembly of collagen-binding peptide with collagen as a bioactive scaffold for osteogenesis in vitro and in vivo. Biomaterials 2007;28(29):4257–4267.
264. Lee JY, Choo JE, Park HJ, Park JB, Lee SC, Jo I, Lee SJ, Chung CP, Park YJ. Injectable gel with synthetic collagen-binding peptide for enhanced osteogenesis in vitro and in vivo. Biochem Biophys Res Commun 2007;357(1):68–74.
265. 2+/calmodulin-dependent protein kinase II/ERK/AP-1 signaling pathway in human bone marrow-derived mesenchymal stem cells. Cell Signal 2008;20(4):613–624.
266. Park YS, Lee JY, Suh JS, Jin YM, Yu Y, Kim HY, Park YJ, Chung CP, Jo I. Selective osteogenesis by a synthetic mineral inducing peptide for the treatment of osteoporosis. Biomaterials 2014;35(37):9747–9754.
267. Shin H, Zygourakis K, Farach-Carson MC, Yaszemski MJ, Mikos AG. Attachment, proliferation, and migration of marrow stromal osteoblasts cultured on biomimetic hydrogels modified with an osteopontin-derived peptide. Biomaterials 2004;25(5):895–906.
268. Choi YJ, Lee JY, Chung C-P, Park YJ. Enhanced osteogenesis by collagen-binding peptide from bone sialoprotein in vitro and in vivo. J Biomed Mater Res 2013;101A(2):547–554.
269. Marie PJ. Targeting integrins to promote bone formation and repair. Nat Rev Endocrinol 2013;9(5):288–295.
270. Srouji S, Ben-David D, Fromigue O, Vaudin P, Kuhn G, Muller R, Livne E, Marie PJ. Lentiviral-mediated integrin alpha5 expression in human adult mesenchymal stromal cells promotes bone repair in mouse cranial and long-bone defects. Hum Gene Ther 2012;23(2):167–172.
271. Hamidouche Z, Fromigue O, Ringe J, Haupl T, Marie PJ. Crosstalks between integrin alpha 5 and IGF2/IGFBP2 signalling trigger human bone marrow-derived mesenchymal stromal osteogenic differentiation. BMC Cell Biol 2010;11(44):1471–2121.
272. Hamidouche Z, Fromigue O, Ringe J, Haupl T, Vaudin P, Pages JC, Srouji S, Livne E, Marie PJ. Priming integrin alpha5 promotes human mesenchymal stromal cell osteoblast differentiation and osteogenesis. Proc Natl Acad Sci USA 2009;106(44):18587–18591.
273. Mould AP, Askari JA, Humphries MJ. Molecular basis of ligand recognition by integrin alpha 5beta 1. I. Specificity of ligand binding is determined by amino acid sequences in the second and third NH2-terminal repeats of the alpha subunit. J Biol Chem 2000;275(27):20324–20336.
274. Koivunen E, Wang B, Ruoslahti E. Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J Cell Biol 1994;124(3):373–380.
275. Fromigue O, Brun J, Marty C, Da Nascimento S, Sonnet P, Marie PJ. Peptide-based activation of alpha5 integrin for promoting osteogenesis. J Cell Biochem 2012;113(9):3029–3038.
276. Saidak Z, Le Henaff C, Azzi S, Marty C, Da Nascimento S, Sonnet P, Marie PJ. Wnt-β-catenin signaling mediates osteoblast differentiation triggered by peptide-induced α5β1 integrin priming in mesenchymal skeletal cells. J Biol Chem 2015;290(11):6903–6912.
277. Gandavarapu NR, Alge DL, Anseth KS. Osteogenic differentiation of human mesenchymal stem cells on alpha5 integrin binding peptide hydrogels is dependent on substrate elasticity. Biomater Sci 2014;2(3):352–361.
278. Frith JE, Mills RJ, Hudson JE, Cooper-White JJ. Tailored integrin-extracellular matrix interactions to direct human mesenchymal stem cell differentiation. Stem Cells Dev 2012;21(13):2442–2456.
279. Sprowson AP, McCaskie AW, Birch MA. ASARM-truncated MEPE and AC-100 enhance osteogenesis by promoting osteoprogenitor adhesion. J Orthop Res 2008;26(9):1256–1262.
280. Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 2000;67(1):54–68.
281. Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 2004;34(2):303–319.
282. Hayashibara T, Hiraga T, Yi B, Nomizu M, Kumagai Y, Nishimura R, Yoneda T. A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo. J Bone Miner Res 2004;19(3):455–462.
283. Nagel DE, Khosla S, Sanyal A, Rosen DM, Kumagai Y, Riggs BL. A fragment of the hypophosphatemic factor, MEPE, requires inducible cyclooxygenase-2 to exert potent anabolic effects on normal human marrow osteoblast precursors. J Cell Biochem 2004;93(6):1107–1114.
284. Vordemvenne T, Paletta J, Hartensuer R, Pap T, Raschke M, Ochman S. Cooperative effects in differentiation and proliferation between PDGF-BB and matrix derived synthetic peptides in human osteoblasts. BMC Musculoskel Dis 2011;12(263):1–7.
285. Liu H, Li W, Gao C, Kumagai Y, Blacher RW, DenBesten PK. Dentonin, a fragment of MEPE, enhanced dental pulp stem cell proliferation. J Dent Res 2004;83(6):496–499.
286. Acharya B, Chun S-Y, Kim S-Y, Moon C, Shin H-I, Park EK. Surface immobilization of MEPE peptide onto HA/β-TCP ceramic particles enhances bone regeneration and remodeling. J Biomed Mater Res Part B Appl Biomater 2012;100B(3):841–849.
287. Yang S, Alnaqeeb M, Simpson H, Goldspink G. Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch. J Muscle Res Cell Motil 1996;17(4):487–495.
288. Goldspink G. Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology 2005;20:232–238.
289. McKoy G, Ashley W, Mander J, Yang SY, Williams N, Russell B, Goldspink G. Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation. J Physiol 1999;516(Pt 2):583–592.
290. Hill M, Goldspink G. Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage. J Physiol 2003;549(Pt 2):409–418.
291. Dai Z, Wu F, Yeung EW, Li Y. IGF-IEc expression, regulation and biological function in different tissues. Growth Horm IGF Res 2010;20(4):275–281.
292. Peng Q, Qiu J, Sun J, Yang L, Zhang B, Wang Y. The nuclear localization of MGF receptor in osteoblasts under mechanical stimulation. Mol Cell Biochem 2012;369(1–2):147–156.
293. Deng M, Zhang B, Wang K, Liu F, Xiao H, Zhao J, Liu P, Li Y, Lin F, Wang Y. Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits. Int Orthop 2011;35(7):1099–1106.
294. Xin C, Bingbing Z, Yuanliang W, Chengyu X, Li Y, Moyuan D, Qin P, Yuxiao L. Mechano-growth factor E peptide inhibits the differentiation and mineralization of osteoblasts. Arch Oral Biol 2012;57(6):720–727.
295. Li Y, Wang Y, Wang P, Zhang B, Yan W, Sun J, Pan J. In vitro cytocompatibility evaluation of MGF-Ct24E chemically grafted and physically blended with maleic anhydride modified poly(D, L-lactic acid). J Biomater Sci Polym Ed 2013;24(7):849–864.
296. Cui H, Yi Q, Feng J, Yang L, Tang L. Mechano growth factor E peptide regulates migration and differentiation of bone marrow mesenchymal stem cells. J Mol Endocrinol 2014;52(2):111–120.
297. Xin J, Wang Y, Wang Z, Lin F. Functional and transcriptomic analysis of the regulation of osteoblasts by mechano-growth factor E peptide. Biotechnol Appl Biochem 2014;61(2):193–201.
298. Deng M, Liu P, Xiao H, Zhang Y, Wang Y, Zhao J, Xu J. Improving the osteogenic efficacy of BMP2 with mechano growth factor by regulating the signaling events in BMP pathway. Cell Tissue Res 2015;361(3):723–731.
299. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou M-X, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;251(2):471–476.
300. Habata Y, Fujii R, Hosoya M, Fukusumi S, Kawamata Y, Hinuma S, Kitada C, Nishizawa N, Murosaki S, Kurokawa T, Onda H, Tatemoto K, Fujino M. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim Biophys Acta 1999;13(1):25–35.
301. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, Osmond DH, George SR, O'Dowd BF. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 2000;74(1):34–41.
302. Xie H, Tang S-y, Cui R-r, Huang J, Ren X-h, Yuan L-q, Lu Y, Yang M, Zhou H-D, Wu X-P, Luo X-H, Liao E-Y. Apelin and its receptor are expressed in human osteoblasts. Regul Peptides 2006;134(2–3):118–125.
303. Xie H, Yuan L-Q, Luo X-H, Huang J, Cui R-R, Guo L-J, Zhou H-D, Wu X-P, Liao E-Y. Apelin suppresses apoptosis of human osteoblasts. Apoptosis 2007;12(1):247–254.
304. Tang S-Y, Xie H, Yuan L-Q, Luo X-H, Huang J, Cui R-R, Zhou H-D, Wu X-P, Liao E-Y. Apelin stimulates proliferation and suppresses apoptosis of mouse osteoblastic cell line MC3T3-E1 via JNK and PI3-K/Akt signaling pathways. Peptides 2007;28(3):708–718.
305. Zhang H, Xie H, Zhao Q, Xie GQ, Wu XP, Liao EY, Luo XH. Relationships between serum adiponectin, apelin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in post-menopausal Chinese women. J Endocrinol Invest 2010;33(10):707–711.
306. Wattanachanya L, Lu WD, Kundu RK, Wang L, Abbott MJ, O'Carroll D, Quertermous T, Nissenson RA. Increased bone mass in mice lacking the adipokine apelin. Endocrinol 2013;154(6):2069–2080.
307. Zeng X, Yu SP, Taylor T, Ogle M, Wei L. Protective effect of apelin on cultured rat bone marrow mesenchymal stem cells against apoptosis. Stem Cell Res 2012;8(3):357–367.
308. Tong Y, Luo JG, Wang R, Wang XB, Kong LY. New cyclic peptides with osteoblastic proliferative activity from Dianthus superbus. Bioorg Med Chem Lett 2012;22(5):1908–1911.
309. Kaur H, Heapy AM, Kowalczyk R, Amso Z, Watson M, Cornish J, Brimble MA. Synthesis and biological evaluation of the osteoblast proliferating cyclic peptides dianthins G and H. Tetrahedron 2014;70(42):7788–7794.
310. Bab I, Gazit D, Chorev M, Muhlrad A, Shteyer A, Greenberg Z, Namdar M, Kahn A. Histone H4-related osteogenic growth peptide (OGP): A novel circulating stimulator of osteoblastic activity. EMBO J 1992;11(5):1867–1873.
311. Bab I, Smith E, Gavish H, Attar-Namdar M, Chorev M, Chen YC, Muhlrad A, Birnbaum MJ, Stein G, Frenkel B. Biosynthesis of osteogenic growth peptide via alternative translational initiation at AUG85 of histone H4 mRNA. J Biol Chem 1999;274(20):14474–14481.
312. Greenberg Z, Chorev M, Muhlrad A, Shteyer A, Namdar-Attar M, Casap N, Tartakovsky A, Vidson M, Bab I. Structural and functional characterization of osteogenic growth peptide from human serum: Identity with rat and mouse homologs. J Clin Endocrinol Metab 1995;80(8):2330–2335.
313. Gavish H, Bab I, Tartakovsky A, Chorev M, Mansur N, Greenberg Z, Namdar-Attar M, Muhlrad A. Human α2-macroglobulin is an osteogenic growth peptide-binding protein. Biochemistry 1997;36(48):14883–14888.
314. Gurevitch O, Slavin S, Muhlrad A, Shteyer A, Gazit D, Chorev M, Vidson M, Namdar-Attar M, Berger E, Bleiberg I, Bab I. Osteogenic growth peptide increases blood and bone marrow cellularity and enhances engraftment of bone marrow transplants in mice. Blood 1996;88(12):4719–4724.
315. Brager MA, Patterson MJ, Connolly JF, Nevo Z. Osteogenic growth peptide normally stimulated by blood loss and marrow ablation has local and systemic effects on fracture healing in rats. J Orthop Res 2000;18(1):133–139.
316. Sun YQ, Ashhurst DE. Osteogenic growth peptide enhances the rate of fracture healing in rabbits. Cell Biol Int 1998;22(4):313–319.
317. Gabet Y, Muller R, Regev E, Sela J, Shteyer A, Salisbury K, Chorev M, Bab I. Osteogenic growth peptide modulates fracture callus structural and mechanical properties. Bone 2004;35(1):65–73.
318. Zhao Z-Y, Shao L, Zhao H-M, Zhong Z-H, Liu J-Y, Hao C-G. Osteogenic growth peptide accelerates bone healing during distraction osteogenesis in rabbit tibia. J Int Med Res 2011;39(2):456–463.
319. Smith E, Meyerrose TE, Kohler T, Namdar-Attar M, Bab N, Lahat O, Noh T, Li J, Karaman MW, Hacia JG, Chen TT, Nolta JA, Muller R, Bab I, Frenkel B. Leaky ribosomal scanning in mammalian genomes: Significance of histone H4 alternative translation in vivo. Nucleic Acids Res 2005;33(4):1298–1308.
320. Horii A, Wang X, Gelain F, Zhang S. Biological designer self-assembling peptide nanofiber scaffolds significantly enhance osteoblast proliferation, differentiation and 3-D migration. PLoS One 2007;2(2):e190.
321. Shuqiang M, Kunzheng W, Xiaoqiang D, Wei W, Mingyu Z, Daocheng W. Osteogenic growth peptide incorporated into PLGA scaffolds accelerates healing of segmental long bone defects in rabbits. J Plast Reconstr Aesthet Surg 2008;61(12):1558–1560.
322. Zhu HB, Guo DZ, Yang SJ, Zhang YH, Wang H, Guo HT, Zhang Y, Cheng DC. Osteogenic actions of the osteogenic growth peptide on bovine marrow mesenchymal stromal cells in culture. Vet Med 2008;53(9):501–509.
323. Robinson D, Bab I, Nevo Z. Osteogenic growth peptide regulates proliferation and osteogenic maturation of human and rabbit bone marrow stromal cells. J Bone Miner Res 1995;10(5):690–696.
324. Fei Q, Guo C, Xu X, Gao J, Zhang J, Chen T, Cui D. Osteogenic growth peptide enhances the proliferation of bone marrow mesenchymal stem cells from osteoprotegerin-deficient mice by CDK2/cyclin A. Acta Biochim Biophys Sin 2010;42(11):801–806.
325. Chen Z, Wang X, Shao Y, Shi D, Chen T, Cui D, Jiang X. Synthetic osteogenic growth peptide promotes differentiation of human bone marrow mesenchymal stem cells to osteoblasts via RhoA/ROCK pathway. Mol Cell Biochem 2011;358(1–2):221–227.
326. Greenberg Z, Chorev M, Muhlrad A, Shteyer A, Namdar M, Mansur N, Bab I. Mitogenic action of osteogenic growth peptide (OGP): role of amino and carboxy-terminal regions and charge. Biochim Biophys Acta 1993;1178(3):273–280.
327. Gabarin N, Gavish H, Muhlrad A, Chen Y-C, Namdar-Attar M, Nissenson RA, Chorev M, Bab I. Mitogenic Gi protein-MAP kinase signaling cascade in MC3T3-E1 osteogenic cells: Activation by C-terminal pentapeptide of osteogenic growth peptide [OGP(10–14)] and attenuation of activation by cAMP. J Cell Biochem 2001;81(4):594–603.
328. Spreafico A, Frediani B, Capperucci C, Leonini A, Gambera D, Ferrata P, Rosini S, Di Stefano A, Galeazzi M, Marcolongo R. Osteogenic growth peptide effects on primary human osteoblast cultures: Potential relevance for the treatment of glucocorticoid-induced osteoporosis. J Cell Biochem 2006;98(4):1007–1020.
329. Chen Z-X, Chang M, Peng Y-L, Zhao L, Zhan Y-R, Wang L-J, Wang R. Osteogenic growth peptide C-terminal pentapeptide [OGP(10–14)] acts on rat bone marrow mesenchymal stem cells to promote differentiation to osteoblasts and to inhibit differentiation to adipocytes. Regul Peptides 2007;142(1–2):16–23.
330. Miguel SMS, Namdar-Attar M, Noh T, Frenkel B, Bab I. ERK1/2-activated de novo Mapkapk2 synthesis is essential for osteogenic growth peptide mitogenic signaling in osteoblastic cells. J Biol Chem 2005;280(45):37495–37502.
331. Mattii L, Battolla B, Moscato S, Fazzi R, Galimberti S, Bernardini N, Dolfi A, Petrini M. The small peptide OGP(10–14) acts through Src kinases and RhoA pathways in Mo-7e cells: Morphologic and immunologic evaluation. Med Sci Monit 2008;14(6):103–108.
332. Chen YC, Bab I, Mansur N, Namdar-Attar M, Gavish H, Vidson M, Muhlrad A, Shteyer A, Chorev M. Structure–bioactivity of C-terminal pentapeptide of osteogenic growth peptide [OGP(10–14)]. J Pept Res 2000;56(3):147–156.
333. Chen YC, Muhlrad A, Shteyer A, Vidson M, Bab I, Chorev M. Bioactive pseudopeptidic analogues and cyclostereoisomers of osteogenic growth peptide C-terminal pentapeptide, OGP(10–14). J Med Chem 2002;45(8):1624–1632.
334. Moore NM, Lin NJ, Gallant ND, Becker ML. The use of immobilized osteogenic growth peptide on gradient substrates synthesized via click chemistry to enhance MC3T3-E1 osteoblast proliferation. Biomaterials 2010;31(7):1604–1611.
335. Panseri S, Russo L, Montesi M, Taraballi F, Cunha C, Marcacci M, Cipolla L. Bioactivity of surface tethered osteogenic growth peptide motifs. Med Chem Commun 2014;5(7):899–903.
336. Fukushima N, Hiraoka K, Shirachi I, Kojima M, Nagata K. Isolation and characterization of a novel peptide, osteoblast activating peptide (OBAP), associated with osteoblast differentiation and bone formation. Biochem Biophys Res Commun 2010;400(1):157–163.
337. Ji M, Leem KH, Kim M, Kim HK. Egg yolk soluble protein stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biosci Biotechnol Biochem 2007;71(5):1327–1329.
338. Kim HK, Lee S, Leem KH. Protective effect of egg yolk peptide on bone metabolism. Menopause 2011;18(3):307–313.
339. Kim HK, Kim MG, Leem KH. Effects of egg yolk-derived peptide on osteogenic gene expression and MAPK activation. Molecules 2014;19(9):12909–12924.
340. Hipskind RA, Bilbe G. MAP kinase signaling cascades and gene expression in osteoblasts. Front Biosci 1998;1(3):d804–d816.
341. Abdou AM, Watabe K, Yamane T, Isono T, Okamura Y, Kawahito S, Takeshima K, Masuda K, Kim M. Antiosteoporotic effect of orally administered yolk-derived peptides on bone mass in women. Food Sci Nutr 2014;2(3):193–199.
342. Glenn KC, Frost GH, Bergmann JS, Carney DH. Synthetic peptides bind to high-affinity thrombin receptors and modulate thrombin mitogenesis. Pept Res 1988;1(2):65–73.
343. Fife C, Mader JT, Stone J, Brill L, Satterfield K, Norfleet A, Zwernemann A, Ryaby JT, Carney DH. Thrombin peptide Chrysalin stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study. Wound Repair Regen 2007;15(1):23–34.
344. Ryaby J, Carney D, Campbell M, Crowther R, Yang J, Bain S, Simmons D. Acceleration of fresh fracture healing with an injectable thrombin peptide in a rat model. Trans ORS 2000;25:877.
345. Wang H, Li X, Tomin E, Doty SB, Lane JM, Carney DH, Ryaby JT. Thrombin peptide (TP508) promotes fracture repair by up-regulating inflammatory mediators, early growth factors, and increasing angiogenesis. J Orthop Res 2005;23(3):671–679.
346. Wang H, Li X, Tomin E, Doty SB, Lane JM, Carney DH, Ryaby JT. Thrombin peptide (TP508) promotes fracture repair by up-regulating inflammatory mediators, early growth factors, and increasing angiogenesis. J Orthop Res 2005;23(3):671–679.
347. Li X, Wang H, Touma E, Qi Y, Rousseau E, Quigg RJ, Ryaby JT. TP508 accelerates fracture repair by promoting cell growth over cell death. Biochem Biophys Res Commun 2007;364(1):187–193.
348. Li G, Cui Y, McIlmurray L, Allen WE, Wang H. rhBMP-2, rhVEGF(165), rhPTN and thrombin-related peptide, TP508 induce chemotaxis of human osteoblasts and microvascular endothelial cells. J Orthop Res 2005;23(3):680–685.
349. Li G, Ryaby JT, Carney DH, Wang H. Bone formation is enhanced by thrombin-related peptide TP508 during distraction osteogenesis. J Orthop Res 2005;23(1):196–202.
350. Cakarer S, Olgac V, Aksakalli N, Tang A, Keskin C. Acceleration of consolidation period by thrombin peptide 508 in tibial distraction osteogenesis in rats. Br J Oral Maxillofac Surg 2010;48(8):633–636.
351. Hanratty BM, Ryaby JT, Pan XH, Li G. Thrombin related peptide TP508 promoted fracture repair in a mouse high energy fracture model. J Orthop Surg Res 2009;4(1):4–1.
352. Sheller MR, Crowther RS, Kinney JH, Yang J, Di Jorio S, Breunig T, Carney DH, Ryaby JT. Repair of rabbit segmental defects with the thrombin peptide, TP508. J Orthop Res 2004;22(5):1094–1099.
353. Hedberg EL, Kroese-Deutman HC, Shih CK, Crowther RS, Carney DH, Mikos AG, Jansen JA. Effect of varied release kinetics of the osteogenic thrombin peptide TP508 from biodegradable, polymeric scaffolds on bone formation in vivo. J Biomed Mater Res 2005;72A(4):343–353.
354. Wang Y, Wan C, Szoke G, Ryaby JT, Li G. Local injection of thrombin-related peptide (TP508) in PPF/PLGA microparticles-enhanced bone formation during distraction osteogenesis. J Orthop Res 2008;26(4):539–546.
355. Ryaby JT, Sheller MR, Levine BP, Bramlet DG, Ladd AL, Carney DH. Thrombin peptide TP508 stimulates cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues. J Bone Joint Surg Am 2006;3:132–139.
356. Carney DH, Olszewska-Pazdrak B. Could rusalatide acetate be the future drug of choice for diabetic foot ulcers and fracture repair? Expert Opin Pharmacother 2008;9(15):2717–2726.
357. Capstone Therapeutics Announces Operational Update. http://capstonethx.com/2012.
358. Chrysalis Biotherapeutics. http://www.chrysbio.com/therapeutic-targets/regenerative-medicine.
359. Viswanathan A, Painter RG, Lanson NA, Wang G. Functional expression of N-formyl peptide receptors in human bone marrow-derived mesenchymal stem cells. Stem Cells 2007;25(5):1263–1269.
360. Marasco WA, Phan SH, Krutzsch H, Showell HJ, Feltner DE, Nairn R, Becker EL, Ward PA. Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. J Biol Chem 1984;259(9):5430–5439.
361. Kim M-K, Min DS, Park YJ, Kim JH, Ryu SH, Bae Y-S. Expression and functional role of formyl peptide receptor in human bone marrow-derived mesenchymal stem cells. FEBS Lett 2007;581(9):1917–1922.
362. Shin MK, Jang YH, Yoo HJ, Kang DW, Park MH, Kim MK, Song JH, Kim SD, Min G, You HK, Choi K-Y, Bae Y-S, Min DS. N-formyl-methionyl-leucyl-phenylalanine (fMLP) promotes osteoblast differentiation via the N-formyl peptide receptor 1-mediated signaling pathway in human mesenchymal stem cells from bone marrow. J Biol Chem 2011;286(19):17133–17143.
363. Christmas P, Callaway J, Fallon J, Jones J, Haigler HT. Selective secretion of annexin 1, a protein without a signal sequence, by the human prostate gland. J Biol Chem 1991;266(4):2499–2507.
364. La M, D'Amico M, Bandiera S, Di Filippo C, Oliani SM, Gavins FN, Flower RJ, Perretti M. Annexin 1 peptides protect against experimental myocardial ischemia-reperfusion: Analysis of their mechanism of action. FASEB J 2001;15(12):2247–2256.
365. Li GF, Pan YZ, Sirois P, Li K, Xu YJ. Iron homeostasis in osteoporosis and its clinical implications. Osteoporos Int 2012;23(10):2403–2408.
366. Sun L, Guo W, Yin C, Zhang S, Qu G, Hou Y, Rong H, Ji H, Liu S. Hepcidin deficiency undermines bone load-bearing capacity through inducing iron overload. Gene 2014;543(1):161–165.
367. Weinberg ED. Role of iron in osteoporosis. Pediatr Endocrinol Rev 2008;1:81–85.
368. Shike H, Shimizu C, Lauth X, Burns JC. Organization and expression analysis of the zebrafish hepcidin gene, an antimicrobial peptide gene conserved among vertebrates. Dev Comp Immunol 2004;28(7–8):747–754.
369. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306(5704):2090–2093.
370. Ma Y, Xu Y-J. A preliminary report of expression of hepcidin gene in SD rats osteoporosis model [J]. Suzhou Univ J Med Sci 2006;26(3):367–369.
371. Huang X. Treatment of osteoporosis in peri- and post- menopausal women with hepcidin. US Patent Application US20100204122 A1. 2010.
372. 2+ channels. Regul Peptides 2011;172(1–3):58–61.
373. Zhang P, Xu YJ, Zhao DY, Ma Y, Xiao L, Feng YS, Du BC, Qian ZM, Li K. Increased intracellular iron and mineralization of cultured hFOB 1.19 cells following hepcidin activation through ferroportin-1. Saudi Med J 2010;31(12):1303–1308.
374. Lu H, Lian L, Shi D, Zhao H, Dai Y. Hepcidin promotes osteogenic differentiation through the bone morphogenetic protein 2/small mothers against decapentaplegic and mitogen-activated protein kinase/P38 signaling pathways in mesenchymal stem cells. Mol Med Rep 2015;11(1):143–150.
375. Zhao GY, Di DH, Wang B, Huang X, Xu YJ. Effects of mouse hepcidin 1 treatment on osteoclast differentiation and intracellular iron concentration. Inflammation 2015;38(2):718–727.
376. Bragdon B, Thinakaran S, Moseychuk O, King D, Young K, Litchfield DW, Petersen NO, Nohe A. Casein kinase 2 beta-subunit is a regulator of bone morphogenetic protein 2 signaling. Biophys J 2010;99(3):897–904.
377. Bragdon B, Thinakaran S, Moseychuk O, Gurski L, Bonor J, Price C, Wang L, Beamer WG, Nohe A. Casein kinase 2 regulates in vivo bone formation through its interaction with bone morphogenetic protein receptor type Ia. Bone 2011;49(5):944–954.
378. Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G, Harris SE, Gallwitz W, Kim KB, Hu S, Crews CM, Mundy GR. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003;111(11):1771–1782.
379. Zhao M, Qiao M, Oyajobi BO, Mundy GR, Chen D. E3 ubiquitin ligase Smurf1 mediates core-binding factor α1/Runx2 degradation and plays a specific role in osteoblast differentiation. J Biol Chem 2003;278(30):27939–27944.
380. Uyama M, Sato MM, Kawanami M, Tamura M. Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib. Genes Cells 2012;17(7):548–558.
381. Shah J, Orlowski R. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 2009;23(11):1964–1979.
382. Bonvini P, Zorzi E, Basso G, Rosolen A. Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia 2007;21:838–842.
383. Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005;131(1):71–73.
384. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M, Mancini C, Martella E, Ferrari L, Tabilio A, Rizzoli V. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007;110(1):334–338.
385. Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 2009;84(1):6–14.
386. Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN, Jones DC, Vallet S, Bouxsein ML, Pozzi S, Chhetri S, Seo YD, Aronson JP, Patel C, Fulciniti M, Purton LE, Glimcher LH, Lian JB, Stein G, Anderson KC, Scadden DT. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008;118(2):491–504.
387. Qiang YW, Hu B, Chen Y, Zhong Y, Shi B, Barlogie B, Shaughnessy JD, Jr. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 2009;113(18):4319–4330.
388. Kaiser MF, Heider U, Mieth M, Zang C, von Metzler I, Sezer O. The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling. Eur J Haematol 2013;90(4):263–272.
389. Zavrski I, Krebbel H, Wildemann B, Heider U, Kaiser M, Possinger K, Sezer O. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun 2005;333(1):200–205.
390. Boissy P, Andersen TL, Lund T, Kupisiewicz K, Plesner T, Delaisse JM. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions. Leuk Res 2008;32(11):1661–1668.
391. Obri A, Makinistoglu MP, Zhang H, Karsenty G. HDAC4 integrates PTH and sympathetic signaling in osteoblasts. J Cell Biol 2014;205(6):771–780.
392. Sanvoranart T, Supokawej A, Kheolamai P, Y UP, Klincumhom N, Manochantr S, Wattanapanitch M, Issaragrisil S. Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues. Biochem Biophys Res Commun 2014;447(4):580–585.
393. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006;116(5):1202–1209.
394. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24(19):3113–3120.
395. Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia 2013;27(2):430–440.
396. Berenson JR, Hilger JD, Yellin O, Dichmann R, Patel-Donnelly D, Boccia RV, Bessudo A, Stampleman L, Gravenor D, Eshaghian S, Nassir Y, Swift RA, Vescio RA. Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy. Leukemia 2014;28(7):1529–1536.
397. Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol 2011;86(6):484–487.
398. Hu B, Chen Y, Usmani SZ, Ye S, Qiang W, Papanikolaou X, Heuck CJ, Yaccoby S, Williams BO, Van Rhee F, Barlogie B, Epstein J, Qiang Y-W. Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. PLoS One 2013;8(9):e74191.
399. Li Y, Li J, Zhuang W, Wang Q, Ge X, Zhang X, Chen P, Fu J, Li B. Carfilzomib promotes the osteogenic differentiation potential of mesenchymal stem cells derived from myeloma patients by inhibiting notch1 activity in vitro. Leuk Res 2014;38(8):970–976.
400. Hilton MJ, Tu X, Wu X, Bai S, Zhao H, Kobayashi T, Kronenberg HM, Teitelbaum SL, Ross FP, Kopan R, Long F. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med 2008;14(3):306–314.
401. Yang Y, Blair HC, Shapiro IM, Wang B. The proteasome inhibitor carfilzomib suppresses parathyroid hormone-induced osteoclastogenesis through a RANKL-mediated signaling pathway. J Biol Chem 2015;290(27):16918–16928.
402. Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006;14(3):451–456.